1
|
Özet A, Dane F, Aykan NF, Yalçın Ş, Evrensel T, Özkan M, Karabulut B, Ormeci MN, Atasev O, Vidot L, Çiçin İ. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Future Oncol 2022; 18:3267-3276. [PMID: 36040321 DOI: 10.2217/fon-2022-0455] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with ≥2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting. Clinical Trial Registration: NCT03306394 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Ahmet Özet
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, 06560, Turkey
| | - Faysal Dane
- Division of Medical Oncology, Department of Internal Medicine, Marmara University Medical Faculty, Istanbul, 34854, Turkey
| | - Nuri Faruk Aykan
- Department of Medical Oncology, Istinye University Medical Faculty, Istanbul, 34010, Turkey
| | - Şuayib Yalçın
- Hacettepe University Institute of Cancer, Department of Medical Oncology, Ankara, 06230, Turkey
| | - Türkkan Evrensel
- Department of Medical Oncology, Uludağ University Medical Faculty, Bursa, 16059, Turkey
| | - Metin Özkan
- Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, 38280, Turkey
| | - Bülent Karabulut
- Department of Medical Oncology, Özel İzmir Kent Hospital, İzmir, 35620, Turkey
| | | | - Ozan Atasev
- Servier Pharmaceuticals, Istanbul, 34398, Turkey
| | - Loïck Vidot
- Servier Pharmaceuticals, Suresnes, 92150, France
| | - İrfan Çiçin
- Department of Medical Oncology, Trakya University, Edirne, 22030, Turkey
| |
Collapse
|